Therapeutic strategies aimed at disrupting Tfh–B-cell interactions, blocking Tfh-derived cytokines, or modulating co-stimulatory pathways (e.g., ICOS and PD-1) may offer effective means of managing autoimmune diseases driven by Tfh-cell dysregulation. This evidence concerns the gene ICOS and autoimmune disease.